BR112021017961A2 - Combinação de agentes antivirais, kit e método de tratamento com base nos mesmos - Google Patents
Combinação de agentes antivirais, kit e método de tratamento com base nos mesmosInfo
- Publication number
- BR112021017961A2 BR112021017961A2 BR112021017961A BR112021017961A BR112021017961A2 BR 112021017961 A2 BR112021017961 A2 BR 112021017961A2 BR 112021017961 A BR112021017961 A BR 112021017961A BR 112021017961 A BR112021017961 A BR 112021017961A BR 112021017961 A2 BR112021017961 A2 BR 112021017961A2
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- kit
- hiv infection
- method based
- treatment
- Prior art date
Links
- 239000003443 antiviral agent Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 208000031886 HIV Infections Diseases 0.000 abstract 3
- 208000037357 HIV infectious disease Diseases 0.000 abstract 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 abstract 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960000366 emtricitabine Drugs 0.000 abstract 1
- 229960001627 lamivudine Drugs 0.000 abstract 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2018147078A RU2726210C2 (ru) | 2018-12-27 | 2018-12-27 | Комбинация противовирусных средств, набор и способ лечения на ее основе |
PCT/RU2019/001031 WO2020139163A2 (fr) | 2018-12-27 | 2019-12-26 | Combinaison de produits antiviraux, ensemble et méthode de traitement sur leur base |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021017961A2 true BR112021017961A2 (pt) | 2021-12-28 |
Family
ID=71130174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021017961A BR112021017961A2 (pt) | 2018-12-27 | 2019-12-26 | Combinação de agentes antivirais, kit e método de tratamento com base nos mesmos |
Country Status (5)
Country | Link |
---|---|
KR (1) | KR20210119408A (fr) |
CN (1) | CN113473994A (fr) |
BR (1) | BR112021017961A2 (fr) |
RU (1) | RU2726210C2 (fr) |
WO (1) | WO2020139163A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2022237405A1 (en) * | 2021-03-15 | 2023-11-02 | Transposon Therapeutics, Inc. | Line-1 inhibitors to treat cns and systemic diseases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040224917A1 (en) * | 2003-01-14 | 2004-11-11 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
RU2331420C2 (ru) * | 2005-12-08 | 2008-08-20 | Роберт Шалвович Бибилашвили | Противовирусное средство (варианты) и способ лечения на его основе |
RU2446169C2 (ru) * | 2010-05-28 | 2012-03-27 | Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ" | Способ получения 5'-аминокарбонилфосфонатов нуклеозидов и способ получения хлорангидрида триметилсилильного эфира этоксикарбонилфосфоновой кислоты |
RU2441016C1 (ru) * | 2010-05-28 | 2012-01-27 | Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ" | Соли 5'-аминокарбонилфосфоната 3'-азидо-3'-дезокситимидина, являющиеся селективными ингибиторами продукции вируса иммунодефицита человека вич-1 |
EP2714045A1 (fr) * | 2011-05-30 | 2014-04-09 | Cipla Limited | Composition pharmaceutique antirétrovirale |
KR101976231B1 (ko) * | 2011-10-14 | 2019-05-07 | 자크리토에 악치오네르노에 오브쉐스토보 "프로이즈보드스트벤노-콤머체스카야 아쏘치아치야 아즈트" | 인간 면역결핍 바이러스 hiv-1 생산의 선별적인 저해제로서 작용하는 카르바모일 포스폰산 에스테르의 염 |
CN104884063A (zh) * | 2012-10-23 | 2015-09-02 | 西普拉有限公司 | 抗逆转录病毒药物组合物 |
-
2018
- 2018-12-27 RU RU2018147078A patent/RU2726210C2/ru active
-
2019
- 2019-12-26 CN CN201980093074.5A patent/CN113473994A/zh active Pending
- 2019-12-26 WO PCT/RU2019/001031 patent/WO2020139163A2/fr active Application Filing
- 2019-12-26 BR BR112021017961A patent/BR112021017961A2/pt not_active IP Right Cessation
- 2019-12-26 KR KR1020217023854A patent/KR20210119408A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020139163A3 (fr) | 2020-08-27 |
RU2726210C2 (ru) | 2020-07-09 |
KR20210119408A (ko) | 2021-10-05 |
RU2018147078A (ru) | 2020-06-29 |
WO2020139163A2 (fr) | 2020-07-02 |
CN113473994A (zh) | 2021-10-01 |
RU2018147078A3 (fr) | 2020-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
CO2022018715A2 (es) | Análogos de nucleósido de 1’-ciano y usos de los mismos | |
BR112012024590A2 (pt) | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos | |
ATE478886T1 (de) | Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c | |
CO2022014073A2 (es) | Compuestos antivirales y métodos para la administración de los mismos | |
BR0316397A (pt) | Tiouréias aril substituìdas e compostos relacionados como inibidores de replicação viral | |
AR082068A2 (es) | Analogos de nucleosidos fluorados modificados | |
UY27875A1 (es) | Prodrogas 2 ' y 3 ' de nucleósidos modificados para tratar flaviviridae | |
PA8588501A1 (es) | Derivados antivirales de nucleósidos | |
BRPI9607851B8 (pt) | combinação e formulação farmacêutica. | |
BR112017026746A2 (pt) | composições de liberação de fármacos implantáveis e métodos de uso dos mesmos | |
BRPI0506705A (pt) | composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos | |
BR112021019931A2 (pt) | Parasiticidas isoxazolina sistêmicos para tratamento ou profilaxia de doença transmitida por vetor e viral | |
BR112022010798A2 (pt) | Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo | |
BR112021017961A2 (pt) | Combinação de agentes antivirais, kit e método de tratamento com base nos mesmos | |
BR112021025394A2 (pt) | Derivados de antraciclina, conjugados de fármaco e molécula de ligação ao alvo, uso de conjugado de fármaco e molécula de ligação ao alvo, método de tratamento de uma doença em um paciente em necessidade de tratamento, e composição farmacêutica | |
BR112023022264A2 (pt) | Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo | |
BR0317539A (pt) | Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais | |
AR039895A1 (es) | Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla | |
AR079000A1 (es) | Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas | |
BR112022019198A2 (pt) | Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma | |
CL2015002627A1 (es) | Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol | |
BR112022019357A2 (pt) | Medicamento/agente para o tratamento de coronavírus, infecções retrovirais e hepatite c | |
CO2023009085A2 (es) | Pauta posológica de levodopa | |
CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2713 DE 03-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |